#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Growth hormone deficiency Advanced systemic mastocytosis Juvenile idiopathic arthritis Adenovirus infection Alternating hemiplegia of childhood Ornithine transcarbamoylase deficiency Fragile X syndrome Amyotrophic lateral sclerosis gene carrier Pancreatic neuroendocrine tumour Cutaneous T-cell lymphoma refractory Anti-neutrophil cytoplasmic antibody positive vasculitis Skin angiosarcoma Leiomyosarcoma metastatic Pulmonary tuberculosis Mycobacterium abscessus infection More trials…

    Learn about Rare Diseases

    Malignant fibrous histiocytoma – Trials in Disease CADASIL Myxofibrosarcoma – Basic Information Immunodeficiency congenital – Basic Information Alexander disease – Trials in Disease Alveolar rhabdomyosarcoma – Trials in Disease Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Hereditary optic atrophy – Treatment Haemophilia – Life with Disease Familial haemophagocytic lymphohistiocytosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Enoxaparin Sodium Sapropterin Dihydrochloride Ranibizumab ATUMELNANT SRSD107 For-6219 Rucaparib SEVABERTINIB SAROGLITAZAR HEMIMAGNESIUM Fingolimod Hydrochloride Ketoprofen Lysine Ciclosporin Sodium Glycocholate Emapalumab Ipratropium Bromide Gadobenate Dimeglumine Deferoxamine Tofacitinib Citrate Onfekafusp Alfa Sodium More therapies…

    Learn about Your Condition

    Metastasis Femur fracture Tuberous sclerosis complex Cervix carcinoma stage II Chronic hepatic failure Testicular germ cell cancer Mitral valve incompetence Corneal graft failure Binge eating Hepatitis D Ventricular extrasystoles Head and neck cancer stage IV Myositis Hyperparathyroidism secondary Cardiac failure congestive More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Graft versus host disease

  • Study on Graft-Versus-Host Disease Prevention Using Cyclophosphamide and Methotrexate in Adults with Blood Cancer Undergoing Matched-Donor Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Graft versus host disease
    Investigated Drugs:
    • Anti-Human T-Lymphocyte Immunoglobulin From Rabbits
    • Clofarabine
    • Busulfan
    France
  • Long-term Study of Ibrutinib for Patients with B-cell Non-Hodgkin’s Lymphoma and Chronic Graft Versus Host Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • Graft versus host disease
    Investigated Drugs:
    • Ibrutinib
    • Nivolumab
    Belgium France Germany Greece Italy Poland +2
  • A study to evaluate the effectiveness of MC0518 (mesenchymal stromal cells) in adults with acute graft-versus-host disease that has not responded to steroids and ruxolitinib

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Acute graft versus host disease
    • Graft versus host disease
    Investigated Drugs:
    • Mesenchymal Stromal Cells, Ex Vivo Cultured
    Italy
  • Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Graft versus host disease
    Investigated Drugs:
    • Allogeneic Faecal Microbiota, Pooled
    • Vancomycin
    France Italy The Netherlands Spain
  • Study of Mesenchymal Stromal Cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Graft versus host disease
    Investigated Drugs:
    • ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES
    Spain
  • Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ibrutinib
    Czechia France Hungary Italy Poland Spain +1
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!